Dellapasqua S, et al. - In premenopausal women receiving letrozole for neoadjuvant endocrine therapy for breast cancer, researchers assessed endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) vs triptorelin (a GnRH agonist). In a random manner, participants (premenopausal women with stage cT2 to 4b, any N, M0; estrogen receptor and progesterone receptor greater than 50%; human epidermal growth factor receptor 2–negative breast cancer) were assigned to triptorelin 3.75 mg administered intramuscularly on day 1 of every cycle or degarelix 240 mg administered subcutaneously (SC) on day 1 of cycle 1 then 80 mg SC on day 1 of cycles 2 through 6, both with letrozole 2.5 mg/day for six 28-day cycles. Two to 3 weeks after the last injection, these participants were operated on. Triptorelin plus letrozole was received by 26 patients and degarelix plus letrozole by 25 patients. According to findings, degarelix vs triptorelin led to a more quick achievement of OFS (time from the first injection to first assessment of centrally assessed estradiol level ≤ 2.72 pg/mL [≤ 10 pmol/L] during neoadjuvant therapy) as well as maintained OFS more effectively. With both degarelix plus letrozole and triptorelin plus letrozole, the observed adverse events were as expected.